

HCV REFERRAL FORM

Phone: (855) 896.9255 Fax: (402) 896.4862 10004 S. 152nd St, Suite A, Omaha NE 68138

Patient Information	PLEASE FAX	X INSURANCE C	ARD (FRONT AND BA	CK)	Prescribe	r Informatio	on		
Last Name	First Name	DOB	Practice/Facility Name						
Address					Address				
City	State		ZIP		City		State	ZIP	
Phone		SSN			Prescriber Name				
Allergies					Prescriber NPI				
Sex Male Female	Weight (kg)		Height (ft,in)		Nurse/Key Contact		Phone/Page	Phone/Pager	
Insurance Plan		Plan ID #	Plan ID #		Fax		Email		
Diagnosis/Clinical Information PLEASE FAX CLINICAL AND LAB INFORMATION									
Diagnosis: B18.2 (Chronic HCV) Other:				Treatment Naive: Yes No (Response): Incomplete Treatement Relapser Null Responder Partial Responder Previous treatment regimen(s): Co-infections: HIV HBV Post-Transplant Pre-Transplant					
Baseline viral load HCV RNA:					CKD Dialysis Other: PPI/H2 Antagonist During Treatment?: Yes No If yes, was patient told to hold? Yes No				
Additional Information Today's Date Delivery Date Deliver to: Special Instructions Home Physician									
Existing treatment New Treatment Start ANTICIPATED OR ACTUAL THERAPY START DATE:/									
Prescription Informa	tion								
MEDICATION DOSE/STRENGTH/DIRECTIONS FOR USE							QTY	REFILLS	
Epclusa® (velpatasvir 100mg/sofosbuvir 400mg		Take one tablet by mouth once daily					28		
Harvoni® (ledipasvir 90mg/sofosbuvir 400mg)	Take or	Take one tablet by mouth once daily					28		
Mavyret® (glecaprevir 100mg/pibrentasvir 40mg		Take three tablets by mouth once daily with food					84		
Vosevi® (sofosbuvir 400mg/velpatasvir 100mg voxilaprevir 100mg)	Take or	Take one tablet by mouth once daily with food					28		
Zepatier® (elbasvir 50mg/grazoprevir 100mg)		Take one tablet by mouth once daily (Please include results of NS5A resistance testing for GT 1a)					28		
Ribasphere® (ribavirin) 200r Tablets/Capsules (unless otherwise specified, pharmacy ence/availability [or insurance prefere be dispensed)	prefer- Take	Takemg by mouth every morning and takem				evening.	28-day		
Anticipated therapy durat	ion: 8 wee	eks 12 w	eeks 16 weel	(S	24 weeks	Other:			
Anaoipatou tilerapy durat	O WCC	,ng 12 W	CONS TO MCCI	1.0	27 WGGR3	VUIGI.			
In order for a brand name product to be	dispensed, the preso	criber must handwrite	e "Brand Necessary" or "Bran	nd Medically I	Necessary," or your s	tate-specific required	l language to prohibit	substitution:	
PRESCRIBER MUST MANUALLY	SIGN - STAMP SI	GNATURE, SIGNA	TURE BY OTHER PERSO	ONNEL ANI	O COMPUTER-GE	NERATED SIGNA	TURES WILL NOT	BE ACCEPTED	

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date)

DISPENSE AS WRITTEN/Do Not Substitute (date)

I authorize Amber Pharmacy and its representatives to act as my agent in order to initiate and execute the insurance prior authorization process and, in doing so, to release clinical information via phone to the appropriate third party payer.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt for